Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three-year trial tests long-term safety of new PNH combination therapy

NCT ID NCT05389449

Ongoing Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study follows patients with a rare blood disease called PNH for up to three years. It tests the long-term safety and effectiveness of adding a drug called danicopan to their standard treatment. The goal is to see if this combination helps control the disease better over time and improves patients' quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Los Angeles, California, 90089, United States

  • Research Site

    Chicago, Illinois, 60612, United States

  • Research Site

    Baltimore, Maryland, 21231, United States

  • Research Site

    Kansas City, Missouri, 64111, United States

  • Research Site

    Long Island City, New York, 11101, United States

  • Research Site

    Cleveland, Ohio, 44195, United States

  • Research Site

    Dallas, Texas, 75390-9047, United States

  • Research Site

    Porto Alegre, 90110-270, Brazil

  • Research Site

    Rio de Janeiro, 20211-080, Brazil

  • Research Site

    Toronto, Ontario, M5G 2C4, Canada

  • Research Site

    Brno, 625 00, Czechia

  • Research Site

    Lille, 59037, France

  • Research Site

    Paris, 75010, France

  • Research Site

    Pessac, 33604, France

  • Research Site

    Pierre-Bénite, 69495, France

  • Research Site

    Athens, 11527, Greece

  • Research Site

    Thessaloniki, 57010, Greece

  • Research Site

    Haifa, 31048, Israel

  • Research Site

    Jerusalem, 91120, Israel

  • Research Site

    Avellino, 83100, Italy

  • Research Site

    Bassano del Grappa, 36061, Italy

  • Research Site

    Florence, 50134, Italy

  • Research Site

    Milan, 20122, Italy

  • Research Site

    Reggio Calabria, 89131, Italy

  • Research Site

    Roma, 161, Italy

  • Research Site

    Bunkyō City, 113 8603, Japan

  • Research Site

    Kyoto, 605-0981, Japan

  • Research Site

    Osaka, 530-8480, Japan

  • Research Site

    Shibuya-ku, 150-8935, Japan

  • Research Site

    Tsukuba, 305-8576, Japan

  • Research Site

    Kota Kinabalu, 88586, Malaysia

  • Research Site

    Kuching, 93200, Malaysia

  • Research Site

    Miri, 98000, Malaysia

  • Research Site

    Gdansk, 80-952, Poland

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 06591, South Korea

  • Research Site

    Suwon, 16247, South Korea

  • Research Site

    Badalona, 8916, Spain

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Majadahonda, 28222, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Airdrie, ML6 0JS, United Kingdom

  • Research Site

    Leeds, LS9 7TF, United Kingdom

  • Research Site

    London, SE5 9RS, United Kingdom

Conditions

Explore the condition pages connected to this study.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA